Two hundred and ten patients with lower back pain from lumbar disc herniation were randomized to receive Bushen Huoxue formula combined with celecoxib (BSHXF; n=104) or celecoxib with placebo (control; n=102). The primary outcome of interest was the Oswestry Disability Index (ODI). Secondary outcomes of interest included Visual Analog Scale (VAS), Roland-Morris Disability Questionnaire (RMDQ), Timed Up and Go Test (TUGT), trunk range of movement (Trunk ROM), and Hospital Anxiety and Depression Scale (HADS). Outcomes were assessed before treatment, on the last day of the treatment, and at 4 and 8 weeks post-treatment. Overall, the results of the study revealed significant improvements in the BSHXF group across all primary and secondary outcomes compared to the control group. This suggests that BSHXF combined with celecoxib significantly enhances pain relief and functional recovery in LBP patients compared to celecoxib alone.